DNA damage repair and cardiovascular diseases

Canadian Journal of Cardiology

Volumn 26, Issue SUPPLA, 2010, Pages 13A-16A

  Shukla, Praphulla C ^a,b,c   Singh, Krishna K ^a,c   Yanagawa, Bobby ^a,c   Teoh, Hwee ^a,c,d,e,f   Verma, Subodh ^a,b,c,d,e,f  

^a Division of Cardiac Surgery   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f Canadian Cardiovascular Research Network   (Canada)

Author keywords

Cardiovascular disease; DNA damage; DNA repair; Oxidative stress

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHLOROQUINE; DNA POLYMERASE; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; HEART FAILURE; HEART INFARCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; TUMOR SUPPRESSOR GENE; HOMEOSTASIS; REVIEW;

CARDIOVASCULAR DISEASES; DNA DAMAGE; DNA REPAIR; HOMEOSTASIS; HUMANS; OXIDATIVE STRESS;

EID: 77952756846     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71055-2     Document Type: Article

References (55)

1. Kunkel TA. The high cost of living. American Association for Cancer Research Special Conference: Endogenous sources of mutations, Fort Myers, Florida, USA, 11-15 November 1998. Trends Genet 1999;15:93-4.
2. Altieri F, Grillo C, Maceroni M, Chichiarelli S. DNA damage and repair: From molecular mechanisms to health implications. Antioxid Redox Signal 2008;10:891-937.
3. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004;38:445-76.
4. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: Induction, repair and significance. Mutat Res 2004;567:1-61.
5. Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: Role of oxidative damage and environmental stresses. Nat Genet 1996;13:25-34.
6. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: An update. Toxicology 2003;193:3-34.
7. Dizdaroglu M. Base-excision repair of oxidative DNA damage by DNA glycosylases. Mutat Res 2005;591:45-59.
8. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002;21:8949-56.
9. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007;6:923-35.
10. Hoeijmakers JH. DNA repair mechanisms. Maturitas 2001;38:17-22; discussion 22-3.
11. Jiricny J. MutLalpha: At the cutting edge of mismatch repair. Cell 2006;126:239-41.
12. Wyman C, Kanaar R. DNA double-strand break repair: All's well that ends well. Annu Rev Genet 2006;40:363-83.
13. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005;577:275-83.
14. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
15. Bartek J, Lukas J. DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol 2007;19:238-45.
16. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006;21:3-9.
17. Stracker TH, Cassell GD, Ward P, et al. The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol 2004;78:441-53.
18. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003;22:5792-812.
19. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000;22:728-37.
20. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006;20:34-46.
21. Bohr VA, Ottersen OP, Tonjum T. Genome instability and DNA repair in brain, ageing and neurological disease. Neuroscience 2007;145:1183-6.
22. Kastan MB. DNA damage responses: Mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 2008;6:517-24.
23. Mercer J, Mahmoudi M, Bennett M. DNA damage, p53, apoptosis and vascular disease. Mutat Res 2007;621:75-86.
24. Perry JJ, Fan L, Tainer JA. Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair. Neuroscience 2007;145:1280-99.
25. Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 2007;3:162-72.
26. Tsutsui H, Ide T, Kinugawa S. Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 2006;8:1737-44.
27. Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis - a review of the epidemiological evidence. Mutat Res 1990;239:163-79.
28. Nasrin N, Mimish LA, Manogaran PS, et al. Cellular radiosensitivity, radioresistant DNA synthesis, and defect in radioinduction of p53 in fibroblasts from atherosclerosis patients. Arterioscler Thromb Vasc Biol 1997;17:947-53.
29. Botto N, Rizza A, Colombo MG, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001;493:23-30.
30. Ramos KS, Partridge CR. Atherosclerosis and cancer: Flip sides of the neoplastic response in mammalian cells? Cardiovasc Toxicol 2005;5:245-55.
31. De Flora S, Izzotti A. Mutagenesis and cardiovascular diseases: Molecular mechanisms, risk factors, and protective factors. Mutat Res 2007;621:5-17.
32. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
33. Su Y, Swift M. Mortality rates among carriers of ataxiatelangiectasia mutant alleles. Ann Intern Med 2000;133:770-8.
34. Swift M, Chase C. Cancer and cardiac deaths in obligatory ataxiatelangiectasia heterozygotes. Lancet 1983;1:1049-50.
35. Yndestad A, Neurauter CG, Oie E, et al. Up-regulation of myocardial DNA base excision repair activities in experimental heart failure. Mutat Res 2009;666:32-8.
36. Barouch LA, Gao D, Chen L, et al. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res 2006;98:119-24.
37. Chan KK, Zhang QM, Dianov GL. Base excision repair fidelity in normal and cancer cells. Mutagenesis 2006;21:173-8.
38. Szabo G, Liaudet L, Hagl S, Szabo C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 2004;61:471-80.
39. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
40. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-45.
41. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001;49:798-807.
42. Xiao CY, Chen M, Zsengeller Z, et al. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 2005;312:891-8.
43. Liaudet L, Szabo E, Timashpolsky L, Virag L, Cziraki A, Szabo C. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: Long-term morphological and functional consequences. Br J Pharmacol 2001;133:1424-30.
44. Szabo G, Soos P, Mandera S, et al. INO-1001 a novel poly(ADPribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 2004;21:426-32.
45. Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg 2002;73:575-81.
46. Schott P, Singer SS, Kogler H, et al. Pressure overload and neurohumoral activation differentially affect the myocardial proteome. Proteomics 2005;5:1372-81.
47. Bupha-Intr T, Holmes JW, Janssen PM. Induction of hypertrophy in vitro by mechanical loading in adult rabbit myocardium. Am J Physiol Heart Circ Physiol 2007;293:H3759-67.
48. Ozaki K, Sato H, Inoue K, et al. SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet 2009;41:329-33.
49. Mai PL, Chatterjee N, Hartge P, et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS One 2009;4:e4812.
50. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25(4 Suppl 10):72-85.
51. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002;300:862-7.
52. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol 1996;271:H2079-85.
53. Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151-7.
54. L'Ecuyer T, Sanjeev S, Thomas R, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006;291:H1273-80.
55. Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006;4:377-89.